FDA warns Mylan about cGMP violations at its Indian facilities

Published: 20-Aug-2015
Regulatory

Includes poor monitoring of staff and the use of gloves containing tears and pinholes


The US FDA has warned Mylan about manufacturing concerns at three of its plants in India.

In a warning letter to the generic drug manufacturer, the FDA said it had found 'significant violations of current good manufacturing practice' during inspections at the plants in August and September last year and in February this year.

The inspections relate to Mylan's Agila Specialty Formulation Facility (SFF), Sterile Product Division (SPD), and Onco Therapies Limited (OTL) sites in Bangalore.

Some of the violations cited were failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products, such as the use of gloves with tears and pinholes, as well as deficiencies in environmental monitoring and poor monitoring of staff.

There is a lack of assurance that you maintain your manufacturing environment in a state of control suitable for aseptic processing

In addition, the FDA found 'unidentified white particles on gloves exposed to critical areas inside the RABS'.

'There is a lack of assurance that you maintain your manufacturing environment in a state of control suitable for aseptic processing,' the FDA said in its warning letter.

According to the FDA, some of these violations were 'recurrent and long-standing' and Mylan's investigations 'inadequate' and 'raise questions about the ability of your current corporate quality system to achieve overall compliance with CGMP'.

Mylan CEO Heather Bresch said in a statement: 'Since Mylan acquired the Agila injectables businesses in December 2013 to create a leading global injectables platform, we have been taking extensive action to integrate the Agila business into Mylan's One Quality Standard, and to ensure our leading position as a high quality, reliable source of injectables for the long term.

'As part of this ongoing process, we have a deep and unwavering commitment to quality everywhere we operate. We have been and will continue to work diligently to address all of the FDA's observations and have made important progress.'

  • Companies:
  • US Food and Drug Administration (FDA)
  • Mylan Pharmaceuticals
See more

You may also like

Regulatory

AstraZeneca's Imfinzi granted priority review and BTD by the US FDA for SCLC

Read more
The therapeutic significantly improved PFS and OS in patients with limited-stage small cell lung cancer in the Phase III ADRIATIC trial

Trending Articles

  1. The right validation model: practical considerations and applications It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  3. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
  4. Accelerating and enhancing toxicology assessments Infographic guides users through ToxHQ’s speedy assessment features
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Why quality control should be intimately combined with sterile product development, manufacturing and the overall product supply chain With sponsor companies increasingly needing to create and launch differentiated, stable, usable and safe injectable treatments for patients, experts at ten23 health are keen to promote the importance of integrating development and/or manufacturing with quality control services

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Regulatory

AstraZeneca's Imfinzi granted priority review and BTD by the US FDA for SCLC

The therapeutic significantly improved PFS and OS in patients with limited-stage small cell lung cancer in the Phase III ADRIATIC trial
Manufacturing

FDA releases guidance to clarify guidelines for 'remanufacturing' devices that need maintenance or repair

The guidelines includes information on reusable product labelling, what it classifies as 'remanufacturing' and how companies can ensure products follow guidelines after multiple uses
Manufacturing

What's in an FDA approval? How a start-up company gets its drug to market

The FDA wields a supreme amount of power in the regulatory realm of the pharmaceutical industry. For smaller start-ups or those newer to the industry, navigating the compliance pathways can prove a daunting task
Regulatory

FDA grants landmark approval for Alzheimer’s treatment

LEQEMBI is the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer’s disease
Regulatory

Sequana submits IND application for heart failure treatment

The IND application includes data from the previously reported GLP animal and Phase 1 CHIHUAHUA studies
Regulatory

FDA grants marketing approval for safety syringes

Zephyrus' needle system contains an internal mechanism that retracts the needle inside the syringe after activation
Regulatory

FDA releases final guidance for upcoming biological product transition

The BPCI Act requires that a marketing application for a “biological product” must be submitted as a biologics license application
Subscribe now